



For Immediate Release

Vaxart to Present at Investor Conferences in March

SOUTH SAN FRANCISCO, Calif., March 7, 2016 — Vaxart, Inc., a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today its CEO, Wouter Latour, MD will present at BioCapital Europe in Amsterdam and the Sachs CEO Forum in Zurich, to be held on March 9 and March 16 respectively.

The presentation will cover Vaxart's proprietary oral vaccine platform and latest developments on its tablet vaccines for RSV, norovirus and influenza. For conference information and investor registration to attend the Vaxart presentation, please visit <http://www.biocapitaleurope.com> and <http://www.sachsforum.com>.

About Vaxart

Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are oral vaccines for RSV, Norovirus and seasonal influenza. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration, are easy to administer, eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. For more information, please visit www.vaxart.com.

###

CONTACT:

Katie Hogan
WCG
415.658.9745
khogan@wcgworld.com

Samir Singh
Vaxart
908-720-6224
ssingh@vaxart.com